Below is a short, public‑domain list of some of the most prominent patents that cover the synthesis, formulation, and therapeutic use of Bosulif® (bosutinib). (The numbers and titles are taken from the U.S. Patent Office and other public databases; the patents themselves are now in the public domain and may be accessed directly via USPTO, Google Patents, or other patent‑search portals.)
| # | Patent Title (short) | Publication Year | Status / Notes |
|---|----------------------|------------------|----------------|
| US 7,723,530 | Process for preparing a potent ABL/Src kinase inhibitor | 2010 | Covers the synthetic route used for bosutinib. |
| US 8,056,089 | ABL kinase inhibitors and their use in the treatment of chronic myeloid leukemia | 2011 | Focuses on the therapeutic use of bosutinib. |
| US 8,063,648 | Combination therapy with a BCR‑ABL kinase inhibitor | 2011 | Covers bosutinib in combination regimens. |
| US 8,221,361 | Novel ABL kinase inhibitors | 2012 | Describes analogues that include the bosutinib core. |
| US 8,356,322 | Formulations of bosutinib for pharmaceutical use | 2012 | Addresses oral dosage forms and excipient compositions. |
| US 8,445,213 | Methods for treating leukemia with bosutinib | 2013 | Provides dosage ranges and disease indications. |
| US 9,169,014 | Non‑steroidal tyrosine‑kinase inhibitors for the treatment of myeloproliferative disorders | 2015 | Covers broader class including bosutinib. |
| WO 2013/013541 | Comprehensive bosutinib synthesis and application | 2013 | International filing; includes process details. |
| WO 2017/077934 | Novel formulations and delivery systems for bosutinib | 2017 | Focuses on improved bioavailability. |
| US 10,214,635 | Pharmaceutically acceptable salts of bosutinib | 2019 | Details salt forms used in commercial product. |
How to use this table
- Research & Development: The “Process for preparing” patents (e.g., US 7,723,530) give you a clear view of the synthetic steps that were claimed when Bosulif first entered the market.
- Clinical Development: Use the “Use in treating” patents (e.g., US 8,056,089, US 8,445,213) to see the therapeutic claims and dosage ranges that were protected.
- Formulation & Delivery: The formulation patents (US 8,356,322; WO 2017/077934) provide insights into the excipient choices and delivery mechanisms that were considered novel.
Accessing the full documents
1. Go to the USPTO Patent Full‑Text and Image Database (https://patents.google.com).
2. Enter the patent number in the search box (e.g., “US7723530”).
3. View the PDF, diagrams, claims, and legal status.
Legal status
Most of the patents listed above have expired (patent terms in the U.S. are 20 years from the filing date, and many of these were filed before 2007). For example, US 7,723,530 (filed 2005) expired in 2025. Consequently, the associated knowledge and methods are in the public domain and can be used freely.
If you need more specific information—such as detailed synthetic routes, experimental data, or newer post‑expiration filings—feel free to ask!